Eterna Therapeutics Inc. (NASDAQ:ERNA) Sees Large Drop in Short Interest

Eterna Therapeutics Inc. (NASDAQ:ERNA) was the target of a significant decrease in short interest in February. As of February 15th, there was short interest totalling 186,600 shares, a decrease of 39.6% from the January 31st total of 309,100 shares. Based on an average trading volume of 10,530,000 shares, the days-to-cover ratio is currently 0.0 days. Currently, 0.5% of the company’s stock are short sold.

Institutional Inflows and Outflows

An institutional investor recently raised its position in Eterna Therapeutics stock. Geode Capital Management LLC increased its stake in shares of Eterna Therapeutics Inc. (NASDAQ:ERNA) by 1,159.2% during the 4th quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 257,310 shares of the company’s stock after acquiring an additional 236,875 shares during the quarter. Geode Capital Management LLC owned approximately 4.76% of Eterna Therapeutics worth $76,000 at the end of the most recent quarter. Institutional investors own 70.55% of the company’s stock.

Eterna Therapeutics Trading Up 2.5 %

NASDAQ ERNA traded up $0.01 on Tuesday, hitting $0.29. 206,868 shares of the company were exchanged, compared to its average volume of 15,572,489. The company has a market cap of $1.55 million, a PE ratio of -0.03 and a beta of 4.29. Eterna Therapeutics has a 12 month low of $0.22 and a 12 month high of $2.63. The stock has a fifty day moving average of $0.35 and a 200-day moving average of $0.79.

Eterna Therapeutics Company Profile

Eterna Therapeutics Inc, a life science company, provides mRNA cell engineering technologies. Its technologies include mRNA cell reprogramming and gene editing; NoveSlice and UltraSlice gene-editing proteins; and the ToRNAdo mRNA delivery system. The company has a license agreement with Factor Bioscience Limited.